Among cancer prognostic marker studies, reporting quality of design and assay information often appears suboptimal, indicating that this literature may be largely unreliable. Given the potential clinical importance of prognostic marker information, improved design and reporting of these studies are warranted.
Yen Thi‐Hai Pham, Ovie Utuama, Claire E. Thomas, Jong A. Park, Carlo La Vecchia, Harvey A. Risch, Chi Thi-Du Tran, Thanh Van Le, Paolo Boffetta, Leon Raskin, Hung N. Luu
A. Cecile J.W. Janssens, John P A Ioannidis, Sara Bedrosian, Paolo Boffetta, Siobhan M. Dolan, Nicole F. Dowling, Isabel Fortier, Andrew N. Freedman, Jeremy Grimshaw, Jeffrey R. Gulcher, Marta Gwinn, Mark A. Hlatky, Holly Janes, Peter Kraft, Stephanie Melillo, Christopher J. O’Donnell, Michael Pencina, David F. Ransohoff, Sheri D. Schully, Daniela Seminara, Deborah M. Winn, Caroline F. Wright, Cornelia M. van Duijn,
Discussion(0)
No comments yet. Be the first to comment.